As Chief Business Officer, Alex Szidon is focused on strategic transactions that will help embed Resilience into the future of next-generation preventative, regenerative and curative therapies and vaccines. In this capacity, Alex and his team support and lead risk-sharing arrangements, equity purchases, newco generation and strategic relationships with academic institutions and life sciences incubators. These transactions span and connect Resilience’s R&D (Res-X) and Digital divisions as well as innovators across Resilience’s modality franchises (cell therapy, gene therapy, nucleic acids, biologics and vaccines).
Alex joined Resilience from Genentech, where he was Vice President, Head of Business Development for Genentech Research and Early Development (gRED). In this capacity Alex drove therapeutic, platform technology, and personalized healthcare transactions in support of gRED’s ambitions to expand its modality expertise, augment computational and data science capabilities and to grow pipeline in regenerative and curative therapies. Prior to Genentech, Alex held business development leadership roles at Merck Research Labs and the Novartis Institutes for BioMedical Research. Earlier in his career, Alex was a co-founder of Zafgen and DARA Biosciences, served as Director of Business Development in the Office of Technology Development at the Harvard Medical School and as a consultant in L.E.K.’s Life Sciences Practice. Alex received his PhD from UCSF in cell biology and biochemistry.